Premium
An open‐label study of the safety and efficacy of limited application of fluticasone propionate ointment, 0.005%, in patients with atopic dermatitis of the face and intertriginous areas
Author(s) -
Tan MeiHeng,
Meador Stacie L.,
Singer Giselle,
Lebwohl Mark G.
Publication year - 2002
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1046/j.1365-4362.2002.01571.x
Subject(s) - intertriginous , medicine , dermatology , fluticasone propionate , atopic dermatitis , telangiectasia , fluticasone , atrophy , corticosteroid , surgery , disease
Background The treatment options for facial and intertriginous skin are limited because these sites are more susceptible to corticosteroid‐induced atrophy. The long‐term management of these corticosteroid‐sensitive sites requires the use of dosing regimens that are effective, but also safe. Methods The affected areas in 21 patients with atopic dermatitis were treated twice daily for 2 weeks, and then once daily for two consecutive days each week for eight more weeks. Results After 2 weeks, treatment success occurred in 95% of facial and intertriginous lesions and also in 95% of nonfacial, nonintertriginous lesions. During long‐term therapy, treatment success was maintained in > 76% of facial and intertriginous lesions, and > 76% of other lesions. Recurrence rates were low, and skin atrophy and telangiectasia did not occur. Conclusions Patients with atopic dermatitis of facial and intertriginous areas were successfully treated with a limited application of fluticasone propionate ointment, 0.005%. The treatment resulted in rapid healing and provided efficacy with a low rate of recurrence and no evidence of skin atrophy or telangiectasia over 8 weeks.